COMMUNIQUÉS West-GlobeNewswire

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
14/09/2026
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune [...]
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
14/09/2026
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events [...]
Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
14/09/2026
Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for [...]
Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors
14/09/2026
As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch process [...]
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
14/09/2026
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related [...]
Sol y Vida Launches Nationwide Bilingual Telehealth Platform Built for Latino Communities
14/09/2026
Launching ahead of Hispanic Heritage Month, Latino-founded health platform provides English- and Spanish-language access to clinician-led weight management, metabolic health and wellness care LOS ANGELES, Sept. 14, 2026 [...]
Etienna Bio Completes FDA INTERACT Meeting for ETB-001
14/09/2026
LEAWOOD, Kan., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc. today announced that it completed an INTERACT meeting with the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) [...]
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
14/09/2026
NANJING, China, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that updated Phase II data for opamtistomig (LBL-024), its [...]
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
14/09/2026
Amivantamab plus chemotherapy demonstrates durable benefit with a differentiated approach that dual targets EGFR and MET 1 Median overall survival reached 34.3 months with the amivantamab-based regimen, the longest [...]
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
14/09/2026
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current [...]
Bio Usawa and Axmed Partner to Expand Access to Affordable Biologic Medicines Across Africa
14/09/2026
Strategic collaboration combines African biologics capabilities with technology-enabled procurement, with an initial focus on retinal diseases KIGALI, Rwanda and BASEL, Switzerland, Sept. 14, 2026 (GLOBE NEWSWIRE) -- [...]
Initiation of Novonesis’ share buyback program
14/09/2026
Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, [...]
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
14/09/2026
Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture [...]
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
14/09/2026
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively Transformation supported by continuing existing [...]
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
14/09/2026
Cellectis fait progresser ses deux programmes in vivo phares, .HEAL-101 et .HEAL-201 dans les dyslipidémies sévères, avec des données préliminaires de phase 1 attendues respectivement au second semestre 2027 et au [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
14/09/2026
COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
14/09/2026
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, today [...]
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
14/09/2026
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One- [...]
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
14/09/2026
L’ensemble des 24 patients a été traité sans toxicité limitant la dose, sans événement indésirable de grade 3 ou supérieur liés à JNJ-1900 (NBTXR3) ou à la procédure d’injection, et l’injection intratumorale a été jugée [...]

Pages